RU2006145905A - Лиганды, связывающие комплекс активатора плазминогена урокиназного типа (upa) и его рецептора (upar), которые ингибируют последующие взаимодействия upar: идентификация и использование в диагностике или терапии - Google Patents
Лиганды, связывающие комплекс активатора плазминогена урокиназного типа (upa) и его рецептора (upar), которые ингибируют последующие взаимодействия upar: идентификация и использование в диагностике или терапии Download PDFInfo
- Publication number
- RU2006145905A RU2006145905A RU2006145905/13A RU2006145905A RU2006145905A RU 2006145905 A RU2006145905 A RU 2006145905A RU 2006145905/13 A RU2006145905/13 A RU 2006145905/13A RU 2006145905 A RU2006145905 A RU 2006145905A RU 2006145905 A RU2006145905 A RU 2006145905A
- Authority
- RU
- Russia
- Prior art keywords
- ligand
- binding
- seq
- upa
- upar
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims 74
- 230000027455 binding Effects 0.000 title claims 46
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 title claims 7
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 title claims 7
- 101150038998 PLAUR gene Proteins 0.000 title 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 230000001225 therapeutic effect Effects 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 238000000034 method Methods 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 238000012360 testing method Methods 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 claims 8
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 5
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 230000006957 competitive inhibition Effects 0.000 claims 3
- 102000006495 integrins Human genes 0.000 claims 3
- 108010044426 integrins Proteins 0.000 claims 3
- 102100037362 Fibronectin Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 2
- 239000007850 fluorescent dye Substances 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 108010053210 Phycocyanin Proteins 0.000 claims 1
- 108010004729 Phycoerythrin Proteins 0.000 claims 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 1
- 108091030071 RNAI Proteins 0.000 claims 1
- 102100035140 Vitronectin Human genes 0.000 claims 1
- 108010031318 Vitronectin Proteins 0.000 claims 1
- 108010004469 allophycocyanin Proteins 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000004709 cell invasion Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000009137 competitive binding Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000009545 invasion Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 claims 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims 1
- 238000003325 tomography Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57389604P | 2004-05-25 | 2004-05-25 | |
| US60/573,896 | 2004-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006145905A true RU2006145905A (ru) | 2008-06-27 |
Family
ID=35451457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006145905/13A RU2006145905A (ru) | 2004-05-25 | 2005-05-25 | Лиганды, связывающие комплекс активатора плазминогена урокиназного типа (upa) и его рецептора (upar), которые ингибируют последующие взаимодействия upar: идентификация и использование в диагностике или терапии |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8101726B2 (enExample) |
| EP (1) | EP1765397B1 (enExample) |
| JP (1) | JP4890449B2 (enExample) |
| KR (1) | KR20070047246A (enExample) |
| CN (1) | CN101022830A (enExample) |
| AU (1) | AU2005248400A1 (enExample) |
| CA (1) | CA2568428C (enExample) |
| DK (1) | DK1765397T3 (enExample) |
| ES (1) | ES2398221T3 (enExample) |
| IL (1) | IL179565A0 (enExample) |
| MX (1) | MXPA06013709A (enExample) |
| PL (1) | PL1765397T3 (enExample) |
| PT (1) | PT1765397E (enExample) |
| RU (1) | RU2006145905A (enExample) |
| WO (1) | WO2005116077A2 (enExample) |
| ZA (1) | ZA200610578B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007109742A2 (en) * | 2006-03-21 | 2007-09-27 | Weaver David T | Methods for humanizing antibodies and humanized antibodies made thereby |
| CN1919874B (zh) * | 2006-09-18 | 2010-09-08 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途 |
| US8105602B2 (en) * | 2006-12-08 | 2012-01-31 | Tactic Pharma, Llc | Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof |
| US8815519B2 (en) | 2006-12-22 | 2014-08-26 | Hvidovre Hospital | Method for predicting cancer and other diseases |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2730282A1 (en) * | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Methods and compositions for the treatment of proteinuric diseases |
| EP2352503B1 (en) * | 2008-11-06 | 2017-07-19 | University of Miami | Role of soluble upar in the pathogenesis of proteinuric kidney disease |
| EP3187877A1 (en) | 2009-09-25 | 2017-07-05 | XOMA Technology Ltd. | Screening methods |
| BR112013016107A2 (pt) | 2010-12-22 | 2017-04-04 | Ifom Fond Inst Firc Di Oncologia Molecolare | molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar |
| CA3027071A1 (en) | 2011-01-14 | 2013-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| TWI700093B (zh) | 2011-03-16 | 2020-08-01 | 法商賽諾菲公司 | 雙重ｖ區類抗體蛋白質之用途 |
| US9867923B2 (en) | 2011-05-09 | 2018-01-16 | University Of Miami | Reducing soluble urokinase receptor in the circulation |
| CN103930128A (zh) | 2011-08-05 | 2014-07-16 | 意大利癌症研究基金会分子肿瘤学研究所(Ifom) | 组成型活性uPAR变体及其在抑制性抗体的生成与分离中的应用 |
| KR102268883B1 (ko) * | 2013-03-15 | 2021-06-28 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해 |
| CN105368859B (zh) * | 2015-11-25 | 2019-10-18 | 王任直 | 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用 |
| US10681506B1 (en) | 2018-04-19 | 2020-06-09 | Tango Tango, Inc. | System and method for push-to-talk over cellular integration with software defined radio |
| US10959062B1 (en) | 2018-04-19 | 2021-03-23 | Tango Tango, Inc. | System and method for push-to-talk over cellular integration with software defined radio |
| WO2020055812A1 (en) | 2018-09-10 | 2020-03-19 | Lung Therapeutics, Inc. | Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis |
| CA3114176A1 (en) * | 2018-09-28 | 2020-04-02 | Jochen Reiser | Supar and prediction and treatment of acute kidney injury |
| EP4051714A4 (en) * | 2019-10-28 | 2023-11-22 | Monash University | ANTIBODIES FOR BINDING PLASMIN |
| CN115867570A (zh) * | 2020-06-15 | 2023-03-28 | 莫诺帕医疗公司 | 精确放射免疫治疗靶向尿激酶纤溶酶原激活剂受体（uPAR）以治疗严重COVID-19疾病 |
| WO2022204267A1 (en) | 2021-03-24 | 2022-09-29 | Alkermes, Inc. | Upar antibodies and fusion proteins with the same |
| EP4341265A4 (en) * | 2021-05-21 | 2025-07-23 | Northstar Medical Tech Llc | TRIVALENT RADIOISTOPE BIO-TARGETED RADIOPHARMACEUTICAL, METHODS OF PREPARATION AND USE |
| CN117715648A (zh) * | 2021-06-11 | 2024-03-15 | 纪念斯隆-凯特琳癌症中心 | 靶向uPAR的抗原识别受体和其用途 |
| CA3246325A1 (en) * | 2022-03-24 | 2023-09-28 | The United States Government As Representative By The Department Of Veterans Affairs | Urokinase-type plasminogen activator receptor-binding peptides and methods of use |
| EP4610269A1 (en) | 2024-02-29 | 2025-09-03 | 3B Pharmaceuticals GmbH | Urokinase plasminogen activator surface receptor (upar) ligands for diagnostic or therapeutic use |
| WO2025207781A1 (en) | 2024-03-26 | 2025-10-02 | Monopar Therapeutics Inc. | Antibody radioisotope constructs |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532132A (en) * | 1993-09-28 | 1996-07-02 | President And Fellows Of Harvard University | Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor |
| DE10117381A1 (de) * | 2001-04-06 | 2002-10-10 | Wilex Biotechnology Gmbh | Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke |
| WO2003079974A2 (en) * | 2002-03-18 | 2003-10-02 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Integrin ligand |
| US8105602B2 (en) * | 2006-12-08 | 2012-01-31 | Tactic Pharma, Llc | Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof |
-
2005
- 2005-05-25 KR KR1020067027198A patent/KR20070047246A/ko not_active Withdrawn
- 2005-05-25 US US11/597,689 patent/US8101726B2/en active Active
- 2005-05-25 CN CNA2005800249140A patent/CN101022830A/zh active Pending
- 2005-05-25 PL PL05754219T patent/PL1765397T3/pl unknown
- 2005-05-25 RU RU2006145905/13A patent/RU2006145905A/ru not_active Application Discontinuation
- 2005-05-25 PT PT57542193T patent/PT1765397E/pt unknown
- 2005-05-25 AU AU2005248400A patent/AU2005248400A1/en not_active Abandoned
- 2005-05-25 EP EP05754219A patent/EP1765397B1/en not_active Expired - Lifetime
- 2005-05-25 JP JP2007515288A patent/JP4890449B2/ja not_active Expired - Lifetime
- 2005-05-25 MX MXPA06013709A patent/MXPA06013709A/es active IP Right Grant
- 2005-05-25 DK DK05754219.3T patent/DK1765397T3/da active
- 2005-05-25 CA CA2568428A patent/CA2568428C/en not_active Expired - Lifetime
- 2005-05-25 WO PCT/US2005/018322 patent/WO2005116077A2/en not_active Ceased
- 2005-05-25 ES ES05754219T patent/ES2398221T3/es not_active Expired - Lifetime
- 2005-05-25 ZA ZA200610578A patent/ZA200610578B/xx unknown
-
2006
- 2006-11-23 IL IL179565A patent/IL179565A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070047246A (ko) | 2007-05-04 |
| IL179565A0 (en) | 2007-05-15 |
| CN101022830A (zh) | 2007-08-22 |
| CA2568428A1 (en) | 2005-12-08 |
| PT1765397E (pt) | 2013-02-04 |
| EP1765397A4 (en) | 2009-05-13 |
| WO2005116077A3 (en) | 2005-12-29 |
| WO2005116077A2 (en) | 2005-12-08 |
| MXPA06013709A (es) | 2008-01-16 |
| US20090180952A1 (en) | 2009-07-16 |
| ZA200610578B (en) | 2009-09-30 |
| EP1765397B1 (en) | 2012-10-24 |
| JP4890449B2 (ja) | 2012-03-07 |
| JP2008509086A (ja) | 2008-03-27 |
| AU2005248400A1 (en) | 2005-12-08 |
| US8101726B2 (en) | 2012-01-24 |
| PL1765397T3 (pl) | 2013-04-30 |
| CA2568428C (en) | 2020-12-29 |
| EP1765397A2 (en) | 2007-03-28 |
| ES2398221T3 (es) | 2013-03-14 |
| DK1765397T3 (da) | 2013-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006145905A (ru) | Лиганды, связывающие комплекс активатора плазминогена урокиназного типа (upa) и его рецептора (upar), которые ингибируют последующие взаимодействия upar: идентификация и использование в диагностике или терапии | |
| JP2008509086A5 (enExample) | ||
| US9217032B2 (en) | Methods for treating colorectal cancer | |
| JP2005526494A5 (enExample) | ||
| US10238716B2 (en) | Anti-P2X7 peptides and epitopes | |
| KR20130028050A (ko) | 유방암을 치료하는 방법 | |
| CA2473686A1 (en) | Novel cytokine zcytor17 ligand | |
| JP2008513536A (ja) | プロガストリンに対するモノクローナル抗体 | |
| EP1516185A2 (en) | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor | |
| JP2007523650A5 (enExample) | ||
| JP2005535562A5 (enExample) | ||
| WO2023219147A1 (ja) | Ｃｃｒ８検出用新規抗ｃｃｒ８抗体 | |
| JP5483023B2 (ja) | がん細胞運動およびがん細胞浸潤抑制剤 | |
| US8609096B2 (en) | Monoclonal antibodies against PCBP-1 antigens, and uses therefor | |
| CN1046759A (zh) | 成视网膜细胞瘤基因产物抗体及其用途 | |
| WO2001053835A2 (en) | Methods for detecting cancer of the central nervous system | |
| US7232891B2 (en) | Anti-human luteinizing hormone-related antibodies and uses thereof | |
| US8703441B2 (en) | Monoclonal antibodies against PCBP-1 antigens, and uses therefor | |
| WO2024155805A2 (en) | Etv1 monoclonal antibodies | |
| HK1011560A1 (en) | Method of diagnosing and treating epithelioma | |
| HK1011560B (en) | Method of diagnosing and treating epithelioma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20091008 |